GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » EPS without NRI

OncoSil Medical (ASX:OSL) EPS without NRI : A$-0.01 (TTM As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical EPS without NRI?

OncoSil Medical's earnings per share without non-recurring items for the six months ended in Jun. 2024 was A$-0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for OncoSil Medical's EPS without NRI or its related term are showing as below:

ASX:OSL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -220.8   Med: -14.5   Max: 67.5
Current: 20.6

ASX:OSL's 3-Year EPS without NRI Growth Rate is ranked better than
67.14% of 697 companies
in the Medical Devices & Instruments industry
Industry Median: 9.2 vs ASX:OSL: 20.60

OncoSil Medical's EPS (Diluted) for the six months ended in Jun. 2024 was A$-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.01.

OncoSil Medical's EPS (Basic) for the six months ended in Jun. 2024 was A$-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.01.


OncoSil Medical EPS without NRI Historical Data

The historical data trend for OncoSil Medical's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSil Medical EPS without NRI Chart

OncoSil Medical Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

OncoSil Medical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - -0.01 - -

Competitive Comparison of OncoSil Medical's EPS without NRI

For the Medical Devices subindustry, OncoSil Medical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSil Medical's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's PE Ratio without NRI falls into.



OncoSil Medical EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSil Medical  (ASX:OSL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


OncoSil Medical EPS without NRI Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSil Medical Business Description

Traded in Other Exchanges
N/A
Address
7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.

OncoSil Medical Headlines

No Headlines